Predictors of Extrahepatic Recurrence After Curative Hepatectomy for Hepatocellular Carcinoma
Akinobu Taketomi(Hokkaido University), Yoshihiko Maehara(Kyushu University), Yuji Soejima(Shinshu University), Hideaki Uchiyama(Kyushu University), Yohei Mano(National Center for Global Health and Medicine), Kazuki Takeishi(University of Pittsburgh), Dai Kitagawa(Kyushu University), Toru Ikegami(Jikei University School of Medicine), K Sugimachi(National Hospital Organization Kyushu Cancer Center), Hiroto Kayashima(Kyushu University), Takeo Toshima(Kyushu University Hospital), Tomonobu Gion(Kyushu University), Yo‐ichi Yamashita(Kumamoto University), Takashi Motomura(Kyushu University), Takashi Maeda(Kyushu University), Shinichi Aishima(Saga University), Ken Shirabe(Gunma University)
Cited by 71
Related Papers
Interleukin‐6/<scp>STAT</scp>3 signaling as a promising target to improve the efficacy of cancer immunotherapy
|Cancer Science|2017|295
Genome-wide Association Study Identifies TNFSF15 and POU2AF1 as Susceptibility Loci for Primary Biliary Cirrhosis in the Japanese Population
|The American Journal of Human Genetics|2012|272
Long‐term and perioperative outcomes of laparoscopic versus open liver resection for hepatocellular carcinoma with propensity score matching: a multi‐institutional Japanese study
|Journal of Hepato-Biliary-Pancreatic Sciences|2015|267
Randomized phase <scp>III</scp> study of gemcitabine, cisplatin plus S‐1 versus gemcitabine, cisplatin for advanced biliary tract cancer (<scp>KHBO1401</scp>‐ <scp>MITSUBA</scp>)
|Journal of Hepato-Biliary-Pancreatic Sciences|2022|244